Clinical Trial Update: Study of KITE-363 or KITE-753 in Participants With Relapsed and/or Refractory B-cell Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update notes that Kite is recruiting participants for a Phase 1/Phase 2 study of KITE-363 or KITE-753 in relapsed and/or refractory B-cell n…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Non-hodgkin Lymphoma

Drugs mentioned

• KITE-363
• KITE-753

Snippet

Sponsor: Kite, A Gilead Company | Conditions: Relapsed and/or Refractory B-cell Lymphoma | Phase 1, Phase 2 | Status: RECRUITING